Symposium 4
Evolving concepts in the management of gliomas
M1, Sat, 2016-05-28 10.30-12.30
Chairpersons
Riccardo Soffietti, Torino, ITALY
Michael Weller, Zurich, SWITZERLAND
- How to integrate molecular markers of prognostic significance in the new WHO classification?
Johan Kros, Rotterdam, THE NETHERLANDS - Will new forms of immunotherapy improve the outcome of glioblastomas?
Michael Weller, Zurich, SWITZERLAND - From chemotherapy to targeted therapy in low grade gliomas
Riccardo Soffietti, Torino, ITALY - New developments in neuroimaging to monitor response and toxicity following antiangiogenic agents
Wolfgang Wick, Heidelberg, GERMANY
Prof. Kros spoke about classification of gliomas based on the gene mutation, and emphasized the assoiation of IDH-1 mutation with low grade tumors, as well as 1p/19q codelation. Mutations in ATRX gene or TP53 are mostly associated with astrocytoma and an EGFR amplification with glioblastomas. The mutation of IDH is typically absent in malignant glioblastomas.
Prof. Weller talked about immunotherapy in glioblastomas. He referred to immune check-point inhibition as an important concept in treatment, i.e. switch on and off the T-cells. New clinical trials use inhibitors of PD-1 receptor and prevent T-cells for becoming inactive, allowing them to fight against cancer cells. Prof. Weller also mentioned that the vaccination trial for EGFR vIII mutation in glioblastomas recently concluded was negative. At the moment the new CAR (Chimeric Antigen Receptor) therapy trial is ongoing.
Prof. Soffietti discussed the need of treatments for low grade gliomas (LGG) as they cause seizures, they grow in size and become malignant over time. He discussed different options after surgery, such as radiotherapy alone or in combination with chemotherapy. He also touched upon anti-epileptic drugs mostly used with brain tumors.
On behalf of Prof. Wick, Prof. Weller talked about using anti-angiogenic agents in glioblastomas. He also discussed about recurrence diagnosis on brain MRI, especially eferring to flair sequence. (#ean2016 )
Valeria Serban, MD, RRFS
